Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Ganfort to Taptiqom in ocular hypertension and open-angle glaucoma
2014-005273-37Phase 4Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of tafluprost + timolol in open-angle glaucoma (OAG), pseudoexfoliation glaucoma (PXG) and ocular hypertension, sponsored by Santen Pharmaceutical. Primary endpoint: Change in conjunctival redness/hyperemia. Started Feb 2015; status: completed.
02
Drugs
tafluprost + timolol
03
Conditions
open-angle glaucoma (OAG)pseudoexfoliation glaucoma (PXG)ocular hypertension
Beyond the preview
Go deeper on 2014-005273-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005273-37.